HealthCare Global Enterprises Limited HCG NSEPHARMA

Q: What is the current share price of HealthCare Global Enterprises Limited (HCG)?

As of 2026-10-23 04:58 IST, HealthCare Global Enterprises Limited (HCG) trades at ₹550.10 on NSE. Its 52-week range is ₹521.75 to ₹776.30.

Q: What is the market capitalisation of HCG?

HealthCare Global Enterprises Limited (HCG) has a market capitalisation of ₹8,213.11 Cr on NSE.

Q: What is the P/E ratio of HCG?

HCG trades at a trailing price-to-earnings (P/E) ratio of 354.90. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 6.40.

Q: What is the return on equity (ROE) of HCG?

HCG has a return on equity (ROE) of 1.03%. Its return on capital employed (ROCE) is 7.00%.

Q: Is HCG a good stock to buy?

This page provides a data-driven analysis of HealthCare Global Enterprises Limited (HCG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Care Facilities · India

https://www.hcgoncology.com

Company Profile ↓

₹550.10

-18.06% 1Y

Mkt Cap₹8,213.11 Cr

P/E354.90

P/B6.40

52W High₹776.30

52W Low₹521.75

Book Value₹92.07

EPS (TTM)₹1.55

Company Overview

HealthCare Global Enterprises Limited provides medical and healthcare services in India and internationally. The company offers cancer diagnostics services, including genomics and molecular diagnostics, digital PET, preventive oncology, physical examination, laboratory tests, home health services, digital pathology, and CTC detection; treatment services, such as medical oncology and haemato-oncology, radiation and surgical oncology, molecular imaging and theranostics, chemotherapy, robotic surgery, actinium and lutetium therapy, immunotherapy, psycho-oncology, targeted drug therapy, bone marrow transplant, pediatric oncology, organ preservation and reconstructive surgery, endocrine therapy, and liver transplant; and post care services, including patient care, psychological support, nutrition, multidisciplinary rehabilitation, and genetic counselling. It also provides cancer screening, interventional radiology, MRI, nephrology, clinical trial, hormone therapy, hematology, CAR T cell, yoga therapy, bone marrow transplant, organ-specific oncology, radiation oncology, liver transplantation, radiology and imaging, clinical laboratory, day care chemotherapy center, home health care, preventive and psycho oncology, translational and nuclear medicine, oncodermatology, paediatric and gynaecologic oncology, anaesthesiology, and orthopaedic oncology. In addition, the company offers gastrointestinal and thoracic oncology, breast surgical oncology, and pain and palliative services. Further, it operates multi-specialty hospitals under the HCG brand that offers inpatient and outpatient treatments with specialties in cardiology, neurology, orthopaedics, gastroenterology, urology, internal medicine and pulmonary, and critical care; and provides oncology diagnostics services, including biomarkers, translational research, and clinical research services under the Triesta Sciences brand. HealthCare Global Enterprises Limited was founded in 1989 and is headquartered in Bengaluru, India.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 14.8% CAGR over the past five years.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

Mar 2026 Revenue of ₹2,538.43 Cr (+14.4% YoY); net profit ₹13.76 Cr.
Trailing 12 Months Year-on-year growth — revenue +13.4%, earnings +170.6%.
5-Year Trend Long-term compounding — revenue CAGR 14.8%, profit CAGR -22.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	14.84%
1 Year:	13.40%

Compounded Profit Growth

5 Years:	-22.31%
1 Year:	170.60%

Stock Price Performance

1 Year:	-18.06%
6 Months:	-4.74%
3 Months:	-17.88%
1 Month:	-21.57%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 11% of range

₹521.75 ₹776.30

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)22.52 · Oversold

Price Performance

1M-21.57%

3M-17.88%

6M-4.74%

1Y-18.06%

Valuation vs Sector

P/E of 354.90 is above the sector median of 36.43 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

NSE TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 14.8% over 5 years.
Generates positive free cash flow.
In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading at a high P/E of 354.9.
Earnings shrank at -22.3% CAGR over 5 years.
Trading 29.1% below its 52-week high.
RSI at 23 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

354.90

Industry PE

36.43

Forward P/E

36.01

PEG Ratio

Book Value

₹92.07

Price to Book

6.40

P/S

3.35

EV/EBITDA

21.88

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

14.84%

Profit 5Y

-22.31%

Revenue (YoY)

13.40%

Earnings (YoY)

170.60%

Profitability & Returns

ROCE

7.00%

ROE

1.03%

ROA

0.35%

Profit Margin

0.87%

Op Margin

7.46%

Gross Margin

36.51%

EPS (Latest Qtr)

₹0.92

EPS (TTM)

₹1.55

Balance Sheet & Liquidity

Debt/Equity

1.23

Quick Ratio

1.06

Current Ratio

1.12

Debt

₹1,735.36 Cr

Total Assets

₹3,922.54 Cr

Current Assets

₹1,135.21 Cr

Working Capital

₹118.05 Cr

Ownership

Promoter Holding

70.64%

Chg in Prom Hold

0.01%

FII / Inst Holding

19.60%

Chg in FII Hold

0.16%

Financial Snapshot

Enterprise Value

₹8,213.11 Cr

Total Revenue (TTM)

₹2,627.35 Cr

EBITDA

₹495.05 Cr

Free Cash Flow

₹55.00 Cr

Operating Cash Flow

₹347.10 Cr

Shares Outstanding

₹14.93 Cr

Gross Margin

36.51%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP ₹	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	HCG HealthCare Global Enterprises Limited NSEPHARMA	550.10	354.90	₹8,213.11 Cr	0.00%	7.00%	1.03%	14.84%	-22.31%
2	SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA	1,745.10	34.62	₹4.19 L Cr	0.91%	17.94%	13.74%	10.39%	10.65%
3	DIVISLAB Divi's Laboratories Limited NSEPHARMA	9,190.00	83.58	₹2.44 L Cr	0.32%	18.96%	15.32%	10.98%	12.08%
4	TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA	4,553.80	72.74	₹1.73 L Cr	0.81%	9.05%	25.79%	13.27%	20.22%
5	ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA	1,117.30	24.90	₹1.11 L Cr	0.09%	19.04%	18.59%	16.55%	36.99%
6	LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA	631.35	164.41	₹1.09 L Cr	0.00%	7.21%	5.65%	35.38%	66.99%
7	APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA	7,600.00	52.32	₹1.09 L Cr	0.25%	19.20%	20.48%	14.85%	33.34%
8	LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA	2,012.50	99.48	₹1.09 L Cr	0.12%	19.53%	16.77%	3.77%	4.00%
9	CIPLA Cipla Limited NIFTY50NSEAIPHARMA	1,314.00	31.51	₹1.06 L Cr	0.99%	14.86%	11.27%	7.23%	11.45%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	441.71 Cr	460.68 Cr	486.94 Cr	469.87 Cr	494.63 Cr	525.58 Cr	553.54 Cr	558.57 Cr	583.43 Cr	611.80 Cr	645.16 Cr	631.18 Cr	650.29 Cr	693.39 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	283.23 Cr	294.89 Cr	313.75 Cr	315.69 Cr	317.04 Cr	336.27 Cr
Gross Profit	-	-	-	-	-	-	-	-	300.20 Cr	316.91 Cr	331.41 Cr	315.49 Cr	333.25 Cr	357.12 Cr
Operating Expenses	365.40 Cr	386.37 Cr	402.32 Cr	391.26 Cr	402.60 Cr	434.68 Cr	451.30 Cr	470.19 Cr	252.55 Cr	267.03 Cr	270.90 Cr	266.53 Cr	270.98 Cr	305.28 Cr
Operating Income	34.11 Cr	33.30 Cr	41.41 Cr	34.45 Cr	46.05 Cr	43.89 Cr	52.50 Cr	31.86 Cr	47.65 Cr	49.88 Cr	60.51 Cr	48.96 Cr	62.27 Cr	51.84 Cr
EBITDA	76.31 Cr	74.31 Cr	84.62 Cr	78.61 Cr	92.03 Cr	90.90 Cr	102.24 Cr	88.38 Cr	115.86 Cr	115.30 Cr	126.24 Cr	99.36 Cr	106.76 Cr	135.32 Cr
Interest Expense	25.63 Cr	25.55 Cr	26.89 Cr	29.46 Cr	26.84 Cr	33.71 Cr	35.98 Cr	40.70 Cr	44.17 Cr	45.47 Cr	43.62 Cr	44.78 Cr	42.70 Cr	39.87 Cr
Pretax Income	13.13 Cr	10.52 Cr	17.92 Cr	11.06 Cr	28.22 Cr	18.99 Cr	27.65 Cr	-3.30 Cr	13.62 Cr	11.92 Cr	19.82 Cr	-6.07 Cr	1.25 Cr	25.03 Cr
Tax Provision	7.48 Cr	6.87 Cr	7.14 Cr	7.63 Cr	4.76 Cr	5.36 Cr	6.97 Cr	11.05 Cr	6.85 Cr	5.94 Cr	-84.00 L	1.83 Cr	-2.79 Cr	8.57 Cr
Net Income	5.65 Cr	3.65 Cr	10.78 Cr	3.43 Cr	23.46 Cr	13.63 Cr	20.68 Cr	7.75 Cr	7.36 Cr	4.75 Cr	16.27 Cr	-9.43 Cr	2.17 Cr	13.77 Cr
Diluted EPS	0.57	0.52	0.92	0.39	1.44	0.82	1.22	0.47	0.52	0.33	1.15	-0.68	0.15	0.92

Profit & Loss (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Revenue	519.00 Cr	584.00 Cr	700.00 Cr	829.00 Cr	976.00 Cr	1,092.00 Cr	1,009.00 Cr	-	1,676.05 Cr	1,889.91 Cr	2,218.14 Cr	2,538.43 Cr
Cost of Revenue	-	-	-	-	-	-	-	-	799.75 Cr	909.99 Cr	1,062.27 Cr	1,241.37 Cr
Gross Profit	-	-	-	-	-	-	-	-	876.29 Cr	979.92 Cr	1,155.87 Cr	1,297.06 Cr
Operating Expenses	443.00 Cr	499.00 Cr	595.00 Cr	713.00 Cr	864.00 Cr	936.00 Cr	887.00 Cr	-	708.04 Cr	822.48 Cr	979.93 Cr	1,075.44 Cr
Operating Income	37.00 Cr	41.00 Cr	48.00 Cr	45.00 Cr	27.00 Cr	9.00 Cr	-37.00 Cr	-	168.25 Cr	157.44 Cr	175.94 Cr	221.62 Cr
EBITDA	76.00 Cr	85.00 Cr	105.00 Cr	116.00 Cr	112.00 Cr	157.00 Cr	122.00 Cr	-	302.75 Cr	342.78 Cr	422.86 Cr	447.66 Cr
Interest Expense	34.00 Cr	38.00 Cr	23.00 Cr	42.00 Cr	70.00 Cr	138.00 Cr	119.00 Cr	-	94.39 Cr	100.69 Cr	154.56 Cr	176.57 Cr
Pretax Income	3.00 Cr	0	35.00 Cr	27.00 Cr	-33.00 Cr	-119.00 Cr	-229.00 Cr	-	44.88 Cr	67.73 Cr	56.96 Cr	26.92 Cr
Tax Provision	-1.68 Cr	-0	11.90 Cr	10.26 Cr	2.31 Cr	-5.95 Cr	6.87 Cr	-	27.25 Cr	26.39 Cr	8.13 Cr	4.14 Cr
Net Income	5.00 Cr	2.00 Cr	23.00 Cr	17.00 Cr	-31.00 Cr	-125.00 Cr	-221.00 Cr	-	29.35 Cr	48.16 Cr	44.41 Cr	13.76 Cr
Diluted EPS	0.11	-0.16	2.44	2.23	-2.66	-11.36	-14.58	-	2.09	3.41	3.12	0.96

Balance Sheet (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Total Assets	776.00 Cr	1,043.00 Cr	1,225.00 Cr	1,440.00 Cr	1,650.00 Cr	2,246.00 Cr	2,031.00 Cr	-	2,316.02 Cr	2,707.50 Cr	3,543.24 Cr	3,922.54 Cr
Current Assets	-	-	-	-	-	-	-	-	580.34 Cr	679.85 Cr	843.80 Cr	1,135.21 Cr
Cash & Equivalents	-	-	-	-	-	-	-	-	174.62 Cr	272.61 Cr	235.87 Cr	536.05 Cr
Inventory	-	-	-	-	-	-	-	-	38.29 Cr	42.67 Cr	53.02 Cr	59.82 Cr
Receivables	-	-	-	-	-	-	-	-	302.51 Cr	294.03 Cr	400.90 Cr	420.70 Cr
Total Liabilities	-	-	-	-	-	-	-	-	1,446.60 Cr	1,842.38 Cr	2,553.19 Cr	2,512.33 Cr
Current Liabilities	-	-	-	-	-	-	-	-	570.32 Cr	743.71 Cr	1,046.42 Cr	1,017.16 Cr
Long Term Debt	-	-	-	-	-	-	-	-	361.74 Cr	485.30 Cr	604.58 Cr	599.19 Cr
Total Debt	349.00 Cr	324.00 Cr	420.00 Cr	464.00 Cr	658.00 Cr	1,347.00 Cr	977.00 Cr	-	901.20 Cr	1,274.36 Cr	1,837.22 Cr	1,735.36 Cr
Total Equity	280.00 Cr	426.00 Cr	433.00 Cr	515.00 Cr	477.00 Cr	382.00 Cr	697.00 Cr	-	860.52 Cr	825.78 Cr	922.44 Cr	1,331.97 Cr
Shares Outstanding	-	-	-	-	-	-	-	-	14.00 Cr	14.02 Cr	14.03 Cr	14.93 Cr

Cash Flows (Annual)

Figures in INR.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Operating Cash Flow	60.00 Cr	73.00 Cr	91.00 Cr	98.00 Cr	98.00 Cr	130.00 Cr	121.00 Cr	-	251.59 Cr	284.58 Cr	317.11 Cr	347.10 Cr
Investing Cash Flow	-79.00 Cr	-204.00 Cr	-210.00 Cr	-283.00 Cr	-238.00 Cr	-101.00 Cr	-171.00 Cr	-	-133.03 Cr	-225.73 Cr	-487.75 Cr	-177.47 Cr
Financing Cash Flow	22.00 Cr	216.00 Cr	89.00 Cr	161.00 Cr	84.00 Cr	-58.00 Cr	112.00 Cr	-	-140.07 Cr	-64.02 Cr	-42.44 Cr	240.67 Cr
Capital Expenditure	-80.00 Cr	-210.00 Cr	-192.00 Cr	-256.00 Cr	-188.00 Cr	-107.00 Cr	-36.00 Cr	-	-133.24 Cr	-185.68 Cr	-208.87 Cr	-292.10 Cr
Free Cash Flow	-20.00 Cr	-137.00 Cr	-101.00 Cr	-158.00 Cr	-90.00 Cr	23.00 Cr	85.00 Cr	-	118.35 Cr	98.90 Cr	108.24 Cr	55.00 Cr
Net Change in Cash	2.00 Cr	85.00 Cr	-29.00 Cr	-24.00 Cr	-56.00 Cr	-30.00 Cr	62.00 Cr	-	-21.51 Cr	-5.16 Cr	-213.08 Cr	410.30 Cr

Ratios (Annual)

Figures in %.

Metric	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Gross Margin %	-	-	-	-	-	-	-	-	52.3%	51.9%	52.1%	51.1%
Operating Margin %	7.1%	7.0%	6.9%	5.4%	2.8%	0.8%	-3.7%	-	10.0%	8.3%	7.9%	8.7%
Net Margin %	1.0%	0.3%	3.3%	2.1%	-3.2%	-11.4%	-21.9%	-	1.8%	2.5%	2.0%	0.5%
ROE %	1.8%	0.5%	5.3%	3.3%	-6.5%	-32.7%	-31.7%	-	3.4%	5.8%	4.8%	1.0%
ROCE %	-	-	-	-	-	-	-	-	9.6%	8.0%	7.0%	7.6%

Shareholding Pattern

Insiders

70.64%

Institutions

19.60%

Public Float

66.78%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for HCG

Google News Sun, 16 Aug 2026

HCG CEO Manish Mattoo sees margin expansion, acquisitions driving next leg of growth - TradingView

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxOVU1GczB1R3hsZ3o4TVpJZDdjX2ZBTHZwSzlHaFBXdTlBeG00N1pmLWhHVzdUZm1UYzl3dVNHTl9NTW9HYlBSRWtGeWNUOTZmZ3JJelBhc1ZqaTFyUXlBbWMtVmZVQ0d4ZWdndmxFWlh1SndTa3pzbjZBWFZLOEtUOFp5Q2JxcjBfMldSTm…

Google News Wed, 20 May 2026

HealthCare Global Enterprises Ltd (NSE:HCG) Q4 2026 Earnings Call Highlights: Strong Revenue ... - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxNSC1pbHVtb0Z2RWplajZYNW4xZnlzMjREQXBzMGw2WmFhbzlWczVtaDNaLVZ5cW1jUWdRUTJjY2J3ZGVNTTdDVHNYSUI5NTd0ajQzMHRTdk1NeF9ISFhGRWpYM3hRUEpocnRZMkxKTmFwR05LT2EzaUhpTGhyX2pMODJ1TG42Q2FUbHlqaT…

Google News Sat, 01 Aug 2026

HCG stock: Can its hospital network finally pay off? - Value Research

<a href="https://news.google.com/rss/articles/CBMikAFBVV95cUxQanVNbTVDYU9SRXdMNjNxZXRsMUM3Z3hxUEYwbzZfdzRGeE41b0NKWmFtVFMtQzVzTmhYVEVXWjZyM3ZMUGdyMXVobW5YUXoyY3Rvc0dhbUNPWUc5MlBMNklxblZIS2hzRnczU1VnQ1g5bUFCZDR0WlhLMlAyTkV6aXI2N1hQcXhzQ19hcU…

Google News ue, 13 Oct 2026

Healthcare Global Enterprises Q2FY27 Results: Earnings call set for Nov 6 - scanx.trade

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxQUE5yd21aMnN1MXc2cDVieGYzUG5ia2ZaLVlyWjV6WktWTkw5c2paR3FNU0hoOTVIems5dzRjcnQ4bEtNanh0TDFkbkdiOUlvUU13ZXh3ZzUzckY3akoydHdSdjlUMXhSMzcwM01YMTBlYXJpUVAweUZ6ZmlzOWFaV09NT25WSU1JVWJoR0…

Google News Fri, 09 Oct 2026

Hospital stocks led by Apollo, Fortis surge up to 4%, but HCG shares fall over 5%; Here's why - CNBC TV18

<a href="https://news.google.com/rss/articles/CBMi-gFBVV95cUxOSEJRbHJud3FlN3VSNXEwUzk3aXVBWVpYdHB1dGdoV0pEYTZ0VnlsYWZNcHdFdDVRSWlla3lZOExqNUNlV0pXOXZWSjdLcE5LMjFwb2U4aWFhSlpoSHdXMGFuSnNLakRjUDFMUmF1VnVjNmh6b18zeXVGQjJRUmhNWVhXMHR0OHI2ZEZqVG…

Google News Wed, 25 Feb 2026

HCG RAISES ₹424 CR THROUGH RIGHTS ISSUE - ICICI Direct

<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxNejA4cG03ME5oV1FFRnlPdjRaQ3U0eHVPMER5S0lMWU9vNXFSOUJWeGE1UVprYzBwNExoOGlQS3RVZk9UbkQtTG40SUh2T1A2ODd3bzhjZy1ZYnJLT1kzd2R2QVJKMDFNMFhiVVM0RS02U29DTFhvSzlVUWdwcHQ5bk5aMjJUbTFQSmhyZ3…

HCG — Frequently Asked Questions

What is the current share price of HealthCare Global Enterprises Limited (HCG)?

As of 2026-10-23 04:58 IST, HealthCare Global Enterprises Limited (HCG) trades at ₹550.10 on NSE. Its 52-week range is ₹521.75 to ₹776.30.

What is the market capitalisation of HCG?

HealthCare Global Enterprises Limited (HCG) has a market capitalisation of ₹8,213.11 Cr on NSE.

What is the P/E ratio of HCG?

HCG trades at a trailing price-to-earnings (P/E) ratio of 354.90. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 6.40.

What is the return on equity (ROE) of HCG?

HCG has a return on equity (ROE) of 1.03%. Its return on capital employed (ROCE) is 7.00%.

Is HCG a good stock to buy?

This page provides a data-driven analysis of HealthCare Global Enterprises Limited (HCG), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks

HealthCare Global Enterprises Limited HCG NSEPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Analyst View

Latest News

HCG CEO Manish Mattoo sees margin expansion, acquisitions driving next leg of growth - TradingView

HealthCare Global Enterprises Ltd (NSE:HCG) Q4 2026 Earnings Call Highlights: Strong Revenue ... - Yahoo Finance

HCG stock: Can its hospital network finally pay off? - Value Research

Healthcare Global Enterprises Q2FY27 Results: Earnings call set for Nov 6 - scanx.trade

Hospital stocks led by Apollo, Fortis surge up to 4%, but HCG shares fall over 5%; Here's why - CNBC TV18

HCG RAISES ₹424 CR THROUGH RIGHTS ISSUE - ICICI Direct

HCG — Frequently Asked Questions

What is the current share price of HealthCare Global Enterprises Limited (HCG)?

What is the market capitalisation of HCG?

What is the P/E ratio of HCG?

What is the return on equity (ROE) of HCG?

Is HCG a good stock to buy?

Explore More